ADC Therapeutics SA (ADCT)

Market Cap	147.63M
Revenue (ttm)	70.84M
Net Income (ttm)	-157.85M
Shares Out	99.08M
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	217,189
Open	1.480
Previous Close	1.520
Day's Range	1.450 - 1.495
52-Week Range	1.390 - 5.380
Beta	1.52
Analysts	Strong Buy
Price Target	8.50 (+470.47%)
Earnings Date	Mar 27, 2025

About ADCT

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to contin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 2020
• Employees: 274
• Stock Exchange: NYSE
• Ticker Symbol: ADCT
• Website: https://www.adctherapeutics.com

Financial Performance

In 2024, ADC Therapeutics's revenue was $70.84 million, an increase of 1.84% compared to the previous year's $69.56 million. Losses were -$157.85 million, -34.25% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 470.47% from the latest price.

Price Target

$8.5

(470.47% upside)

Analyst Consensus: Strong Buy